SCHEMBL3985472

SCHEMBL3985472

COc1cc(N)ccc1NC(=O)N=S(C)(C)=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.51
▸ GAA P10253 3/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ NPC1 O15118 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ ALDH1A1 P00352 6/20 0.44
▸ KMT2A Q03164 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ HTT P42858 2/20 0.40
▸ RAD52 P43351 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ CYP1A1 P04798 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP1B1 Q16678 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3986842 0.89 RAD52 (0.50) MAPTGAASMN1; SMN2ALDH1A1KMT2A
SCHEMBL3989129 0.79 PKM (0.66) MAPTGAASMN1; SMN2ALDH1A1KMT2A
SCHEMBL3986789 0.78 L3MBTL1 (0.40) MAPTGAAALDH1A1HTTGFER
SCHEMBL3985475 0.78 MAPT (0.51) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL2071884 0.77 GAA (0.59) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL6353701 0.77 MAPT (0.59) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL16592515 0.77 GAA (0.59) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL3234161 0.77 LMNA (0.49) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL3979264 0.77 HSD17B10 (0.47) MAPTGAASMN1; SMN2NPC1RAB9A
SCHEMBL3982260 0.77 KDR (0.42) MAPTGAASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2059511-A1 SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2009-05-20 — — EP disclosed
US-20080167330-A1 Carbamoylsulphoximides as protein kinase inhibitors BAYER SCHERING PHARMA AG (DE) 2008-07-10 — — US disclosed
US-20080167330-A1 Carbamoylsulphoximides as protein kinase inhibitors BAYER SCHERING PHARMA AG (DE) 2008-07-10 — — US disclosed
US-20080167330-A1 Carbamoylsulphoximides as protein kinase inhibitors BAYER SCHERING PHARMA AG (DE) 2008-07-10 — — US disclosed
WO-2008025556-A1 SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167330-A1 Carbamoylsulphoximides as protein kinase inhibitors CABLES1, CKS2, CDK2AP1 MAPT 1435/4885GAA 4609/4885SMN1; SMN2 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback